Six patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2032. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jul 2032
Next term end
4
Patent families
When these terms end
Each bar runs from grant to computed term end. 2016 to 2041.20212026203120362041
6 pending applications: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2035 · High confidence
Also notable
Ends Jul 2032 · High confidence
Also notable
Ends Feb 2035 · High confidence
Oxidizing Agent for Modified Nucleotides
US 10,563,248
Cited by 32 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2035.
Methods for Detection of Nucleotide Modification
US 10,428,381
Cited by 32 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
Nucleic Acid Sample Preparation
US 9,822,394
Cited by 26 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 1, 2027The maintenance fee for Methods for Detection of Nucleotide Modification (US 10,428,381) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Oxidizing Agent for Modified Nucleotides (US 10,563,248) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 1 fee due Sep 22, 2027The maintenance fee for Methods for Detection of Nucleotide Modification (US 9,290,807) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods for Analyzing Nucleic Acids | 2 in force | to Jul 2041 |
| Methods for Detection of Nucleotide Modification | 2 in force | to Jul 2032 |
| Oxidizing Agent for Modified Nucleotides | 1 in force | to May 2035 |
| Nucleic Acid Sample Preparation | 1 in force | to Feb 2035 |
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,290,807 | Methods for Detection of Nucleotide Modification In force · High confidence | In force | High confidence | |
| US 10,428,381 | Methods for Detection of Nucleotide Modification In force · High confidence | In force | High confidence | |
| US 9,822,394 | Nucleic Acid Sample Preparation In force · High confidence | In force | High confidence | |
| US 10,563,248 | Oxidizing Agent for Modified Nucleotides In force · High confidence | In force | High confidence | |
| US 11,608,518 | Methods for Analyzing Nucleic Acids In force · High confidence | In force | High confidence | |
| US 12,630,866 | Methods for Analyzing Nucleic Acids In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 6 applications pending · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.